スプリフェルミン新薬の考察と市場予測 - 2032年

当レポートでは、スプリフェルミン新薬の主要6市場（米国、ドイツ、フランス、イタリア、スペイン、英国）およびカナダ市場、韓国市場について調査分析し、作用機序、用法と用量、研究開発活動に関する考察や、市場予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 変形性関節症におけるスプリフェルミンの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品のプロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新治療法）

第5章 スプリフェルミン市場の評価

• 変形性関節症におけるスプリフェルミンの市場見通し
• 主要6市場、カナダ、韓国の分析
  • 主要6市場、カナダ、韓国の変形性関節症向けスプリフェルミンの市場規模
• 市場の分析：国別
  • 米国の変形性関節症向けスプリフェルミンの市場規模
  • ドイツの変形性関節症向けスプリフェルミンの市場規模
  • 英国の変形性関節症向けスプリフェルミンの市場規模
  • カナダの変形性関節症向けスプリフェルミンの市場規模
  • 韓国の変形性関節症向けスプリフェルミンの市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Sprifermin, Clinical Trial Description, 2023
• Table 2: Sprifermin, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Sprifermin Market Size in the 6MM, Canada and Korea, in USD million (2019-2032)
• Table 6: Sprifermin Market Size in the US, in USD million (2019-2032)
• Table 7: Sprifermin Market Size in Germany, in USD million (2019-2032)
• Table 8: Sprifermin Market Size in France, in USD million (2019-2032)
• Table 9: Sprifermin Market Size in Italy, in USD million (2019-2032)
• Table 10: Sprifermin Market Size in Spain, in USD million (2019-2032)
• Table 11: Sprifermin Market Size in the UK, in USD million (2019-2032)
• Table 12: Sprifermin Market Size in Canada, in USD million (2019-2032)
• Table 13: Sprifermin Market Size in Korea, in USD million (2019-2032)

List of Figures

• Figure 1: Sprifermin Market Size in the 6MM, Canada and Korea, USD million (2019-2032)
• Figure 2: Sprifermin Market Size in the United States, USD million (2019-2032)
• Figure 3: Sprifermin Market Size in Germany, USD million (2019-2032)
• Figure 4: Sprifermin Market Size in France, USD million (2019-2032)
• Figure 5: Sprifermin Market Size in Italy, USD million (2019-2032)
• Figure 6: Sprifermin Market Size in Spain, USD million (2019-2032)
• Figure 7: Sprifermin Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Sprifermin Market Size in Canada, USD million (2019-2032)
• Figure 9: Sprifermin Market Size in Korea, USD million (2019-2032)

“"Sprifermin Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about sprifermin for osteoarthritis in the six major markets. A detailed picture of the sprifermin for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the sprifermin for osteoarthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the sprifermin market forecast analysis for osteoarthritis in the 6MM, along with Canada and Korea, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in osteoarthritis.

Drug Summary:

Sprifermin (AS-902330), also known as recombinant human fibroblast growth factor 18 (rhFGF18), is a recombinant form of human fibroblast growth factor 18 (FGF18), which is under development by Merck for the treatment of OA. As a recombinant form of FGF18, sprifermin is a potent agonist of FGFR2 and FGFR3. Sprifermin is delivered by injection into the joint every 6 or 12 months.

As the first recombinant form of human fibroblast growth factor 18 to demonstrate cartilage growth in a controlled clinical study, Sprifermin is at the forefront of next-generation regenerative medicine with the potential to modify the underlying disease pathology in OA.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the sprifermin description, mechanism of action, dosage and administration, research and development activities in osteoarthritis.
• Elaborated details on sprifermin regulatory milestones and other development activities have been provided in this report.
• The report also highlights the sprifermin research and development activities in osteoarthritis across the United States, Europe, Canada and Korea.
• The report also covers the patents information with expiry timeline around sprifermin.
• The report contains forecasted sales of sprifermin for osteoarthritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for osteoarthritis.
• The report also features the SWOT analysis with analyst views for sprifermin in osteoarthritis.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Sprifermin Analytical Perspective by DelveInsight

• In-depth Sprifermin Market Assessment

This report provides a detailed market assessment of sprifermin for osteoarthritis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada and Korea. This segment of the report provides forecasted sales data from 2025 to 2032.

• Sprifermin Clinical Assessment

The report provides the clinical trials information of sprifermin for osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for osteoarthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence sprifermin dominance.
• Other emerging products for osteoarthritis are expected to give tough market competition to sprifermin and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of sprifermin in osteoarthritis.
• Our in-depth analysis of the forecasted sales data of sprifermin from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the sprifermin in osteoarthritis.

Key Questions

• What is the product type, route of administration and mechanism of action of sprifermin?
• What is the clinical trial status of the study related to sprifermin in osteoarthritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the sprifermin development?
• What are the key designations that have been granted to sprifermin for osteoarthritis?
• What is the forecasted market scenario of sprifermin for osteoarthritis?
• What are the forecasted sales of sprifermin in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, along with Canada and Korea?
• What are the other emerging products available and how are these giving competition to sprifermin for osteoarthritis?
• Which are the late-stage emerging therapies under development for the treatment of osteoarthritis?

Table of Contents

1. Report Introduction

2. Sprifermin Overview in Osteoarthritis

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Sprifermin Market Assessment

• 5.1. Market Outlook of Sprifermin in Osteoarthritis
• 5.2. 6MM, Canada and Korea Analysis
  • 5.2.1. Market Size of Sprifermin in the 6MM, Canada and Korea for Osteoarthritis
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Sprifermin in the United States for Osteoarthritis
  • 5.3.2. Market Size of Sprifermin in Germany for Osteoarthritis
  • 5.3.3. Market Size of Sprifermin in France for Osteoarthritis
  • 5.3.4. Market Size of Sprifermin in Italy for Osteoarthritis
  • 5.3.5. Market Size of Sprifermin in Spain for Osteoarthritis
  • 5.3.6. Market Size of Sprifermin in the United Kingdom for Osteoarthritis
  • 5.3.7. Market Size of Sprifermin in Canada for Osteoarthritis
  • 5.3.8. Market Size of Sprifermin in Korea for Osteoarthritis

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options